Clinical trials: Cancer Colon
Colorectal Cancer
A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
The goal of this clinical trial is to test a new smartphone-based program designed to help African American men get screened for colorectal cancer (CRC).
- Trial name
- NCT06052202
- Testing
- CRC mHealth, Control
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ISA Associates, Inc.
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Colon Cancer, Rectum Cancer
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
- Trial name
- NCT00336856
- Testing
- Cetuximab, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Colorectal Cancer
Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up
Screening for colorectal cancer (CRC) not only detects disease early when treatment is more effective but also prevents cancer by finding and removing precancerous polyps.
- Trial name
- NCT04514341
- Testing
- Intervention Phase 1: Provider and Staff education, Intervention Phase 2: Provider and staff education + Patient reminder, Intervention Phase 3: Provider and Staff education + Patient reminder + Patient navigation
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Metastatic Colorectal Cancer
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
- Trial name
- NCT02981524
- Testing
- CY, GVAX, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
This is a Phase 2 multicenter, randomized, parallel arms, double-blind study of vanucizumab to evaluate the efficacy and safety of vanucizumab in combination with oxaliplatin, folinic acid, and 5-fluorouracil (5-FU) (mFOLFOX-6)…
- Trial name
- McCAVE (NCT02141295)
- Testing
- 5-FU, Bevacizumab, Folinic acid
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
PainPac is innovative in its potential to integrate with healthcare systems through electronic medical records (EMRs). PainPac leverages technology to increase patient access to interventions and uses real-time assessment to…
- Trial name
- NCT05686122
- Testing
- PainPac
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Rectal Cancer, Colon Cancer
Perfusion Assessment in Laparoscopic Left Anterior Resection
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic…
- Conditions
- Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp
- Trial name
- PILLAR II (NCT01560377)
- Testing
- PINPOINT Endoscopic Fluorescence Imaging System
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Colorectal Carcinoma
Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma
feasibility of physical activity increase of physical conversation Quality of Life (optional) vascular and metabolic effects
- Trial name
- NCT01210313
- Testing
- Physical exercise
- Where
- 7 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer
Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5…
- Trial name
- POSIBA (NCT01276379)
- Testing
- FOLFIRI (m), FOLFOX-6 (m), Cetuximab
- Where
- 27 sites in Spain
- Volunteers
- 221 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Colorectal Cancer Screening
Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure
This study is designed to determine the optimal bowel preparation regimen for PillCam® COLON 2 Capsule Endoscopy System (CCE) procedures in average risk patients.
- Trial name
- NCT02481219
- Testing
- PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG
- Where
- 6 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Colorectal Cancer
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government.
- Trial name
- STOPCRC (NCT01742065)
- Testing
- Auto Plus
- Where
- 8 sites in United States
- Volunteers
- 62,155 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Colorectal Cancer
Health Literacy Interventions to Overcome Disparities in CRC Screening
In the proposed project the investigators will evaluate two different follow-up approaches to improve low income patients' completion of initial and annual colorectal cancer (CRC) screening using the Fecal Immunochemical Test…
- Trial name
- NCT02360605
- Testing
- automated telephone reminder, prevention coordinator, Health literacy appropriate education and demonstration
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Colon Cancer, Rectal Cancer
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
The purpose of this study is to test a new drug called MK-2206 for metastatic colorectal cancer. This drug is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in certain genes that may make…
- Trial name
- NCT01186705
- Testing
- MK-2206
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC